Co-Diagnostics (CODX) Q4 2024 earnings summary

Executive summary

• Advanced development of PCR platform and test pipeline, focusing on accessibility and affordability in diagnostics for global markets.

• Revenue for 2024 was $3.9 million, down from $6.8 million in 2023, mainly due to lower grant revenue.

• Net loss increased to $37.6 million ($1.24 per share) from $35.3 million ($1.20 per share) year-over-year.

• Completed and withdrew first FDA 510(k) submission for COVID-19 test to address shelf-life stability and incorporate platform improvements; new submission planned.

• Inaugurated new manufacturing facilities in Utah and India to support commercialization and cost-effective production.

Financial highlights

• 2024 total revenue decreased to $3.9 million from $6.8 million year-over-year; grant revenue was $3.1 million, product revenue $0.8 million.

• Gross profit for 2024 was $999,124, down from $4.2 million in 2023.

• Operating expenses decreased to $43.0 million from $45.3 million, mainly due to lower platform development and regulatory costs.

• Net loss was $37.6 million ($1.24 per share) versus $35.3 million ($1.20 per share) prior year.

• Ended the year with $29.7 million in cash, cash equivalents, and marketable securities.

Outlook and guidance

• Plans to resubmit FDA 510(k) for COVID-19 test and initiate clinical evaluations for TB, respiratory multiplex, and HPV tests in 2025.

• Focus on operational efficiency, cost savings, and maintaining a healthy balance sheet.

• Capital requirements to be met through equity financing, additional grants, and operational improvements.